OneAdvanced has been notified of a Drug Safety Update (DSU) published by the Medicines and Healthcare products Regulatory Agency (MHRA) in December 2025 relating to prescribing of Rybelsus ® tablets during a period of transition to a new formulation. This DSU advises that there is a risk of patient harm arising through medication error where both the original and new formulation of Rybelsus ® tablets are available on the market. The original formulation is anticipated to be available until approximately 31st January 2026 however, original formulation stock of imported Rybelsus ® may be within supply chains beyond this date.
Full details are available on the GOV.UK website: https://www.gov.uk/drug-safety-update/rybelsus-r-semaglutide-tablets-transition-to-new-formulation-and-risk-of-medication-error